Lilly bolts on cancer bispecifics with $1.6bn Merus allianceAlways a big player in oncology, Eli Lilly has fallen behind some of its rivals when it comes Share XLilly bolts on cancer bispecifics with $1.6bn Merus alliancehttps://pharmaphorum.com/news/lilly-bolts-on-cancer-bispecifics-with-1-6bn-merus-alliance/
Oxford BioTherapeutics to research cell therapies for Gilead’s KiteGilead Sciences’ Kite unit has teamed up with the UK’s Oxford BioTherapeutics (OBT) to develop a new clutch Share XOxford BioTherapeutics to research cell therapies for Gilead’s Kitehttps://pharmaphorum.com/news/oxford-biotherapeutics-to-research-cell-therapies-for-gileads-kite/
Roche nabs breakthrough tag for TIGIT cancer immunotherapyRoche’s closely-watched combination of two checkpoint inhibitors – TIGIT-targeting tiragolumab and PD-L1 drug Tecentriq – has claimed breakthrough Share XRoche nabs breakthrough tag for TIGIT cancer immunotherapyhttps://pharmaphorum.com/news/roche-nabs-breakthrough-tag-for-tigit-cancer-immunotherapy/
Chasing BMS, J&J files BCMA CAR-T for multiple myeloma to FDAJohnson & Johnson’s Janssen unit has filed a rolling submission for its multiple myeloma CAR-T ciltacabtagene autoleucel (cilta-cel) Share XChasing BMS, J&J files BCMA CAR-T for multiple myeloma to FDAhttps://pharmaphorum.com/news/chasing-bms-jj-files-bcma-car-t-for-multiple-myeloma-to-fda/
Merck cuts $1bn deal with Janux for cancer T-cell therapiesIn a deal that could top $1 billion, Merck & Co has teamed up with US biotech Janux Share XMerck cuts $1bn deal with Janux for cancer T-cell therapieshttps://pharmaphorum.com/news/merck-cuts-1bn-deal-with-janux-for-cancer-t-cell-therapies/
Catamaran joins the CAR-NK fleet, raising $42m in first roundCatamaran Bio has weighed anchor with a $42 million first-round financing that will be used to pull its Share XCatamaran joins the CAR-NK fleet, raising $42m in first roundhttps://pharmaphorum.com/news/catamaran-joins-the-car-nk-fleet-raising-42m-in-first-round/
TGFB for Immuno-Oncology Drug Development SummitAre you interested in finding the next breakthrough in immuno-oncology preclinical or clinical development? Recent scientific, clinical breakthroughs Share XTGFB for Immuno-Oncology Drug Development Summithttps://pharmaphorum.com/events/tgfb-for-immuno-oncology-drug-development-summit/
Five Prime eyes financing after positive results with stomach cancer drugShares in US biotech Five Prime Therapeutics more than tripled after it reported promising trial results with stomach Share XFive Prime eyes financing after positive results with stomach cancer drughttps://pharmaphorum.com/news/five-prime-eyes-financing-after-positive-results-with-stomach-cancer-drug/
Genprex cancer gene therapy paired with AZ, Merck lung cancer drugsAn experimental gene therapy developed by Texas biotech Genprex will be paired with AstraZeneca’s Tagrisso and Merck & Share XGenprex cancer gene therapy paired with AZ, Merck lung cancer drugshttps://pharmaphorum.com/news/genprex-cancer-gene-therapy-paired-with-az-merck-lung-cancer-drugs/